YBGJ — Yubo International Biotech Share Price
Last trade - 00:00- $113.83m
- $113.82m
- $0.60m
- 28
- 23
- 66
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 188.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -197.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.24 | 0.1 | 0.6 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Yubo International Biotech Ltd, formerly Magna-Lab Inc, is a holding company primarily operating through its subsidiary. The Company focuses on the research and development and application of endometrial stem cells and offers its products and services under the brand VIVCELL. The Company’s product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. The Company also offers stem cell related services including cell testing and health management consulting services.
Directors
- Lawrence Minkoff CHM (65)
- Jerome Feldman VPR (70)
- Kenneth Riscica TRS (61)
- Joel Kanter IND (62)
- Seymour Kessler IND (83)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 22nd, 1991
- Public Since
- March 30th, 1993
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 119,820,790
- Address
- Room 105, Building 5, 31 Xishiku Avenue, BEIJING, 00000
- Web
- Phone
- +86 1066155141
- Auditors
- Michael T. Studer CPA
Upcoming Events for YBGJ
Similar to YBGJ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:25 UTC, shares in Yubo International Biotech are trading at $0.95. This share price information is delayed by 15 minutes.
Shares in Yubo International Biotech last closed at $0.95 and the price had moved by +968.62% over the past 365 days. In terms of relative price strength the Yubo International Biotech share price has outperformed the S&P500 Index by +842.81% over the past year.
There is no consensus recommendation for this security.
Yubo International Biotech does not currently pay a dividend.
Yubo International Biotech does not currently pay a dividend.
Yubo International Biotech does not currently pay a dividend.
To buy shares in Yubo International Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.95, shares in Yubo International Biotech had a market capitalisation of $113.83m.
Here are the trading details for Yubo International Biotech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: YBGJ
Based on an overall assessment of its quality, value and momentum Yubo International Biotech is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yubo International Biotech. Over the past six months, its share price has outperformed the S&P500 Index by +53.08%.
As of the last closing price of $0.95, shares in Yubo International Biotech were trading +60.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Yubo International Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Yubo International Biotech's management team is headed by:
- Lawrence Minkoff - CHM
- Jerome Feldman - VPR
- Kenneth Riscica - TRS
- Joel Kanter - IND
- Seymour Kessler - IND